argenx’s Post

The current standard treatment around the world for #IgG4RD is glucocorticoids. But is the role of steroids in treating this disease outsized? 🤔 Hear from John Stone, MD MPH and Wen Zhang, MD PhD their thoughts on the #InflammatoryDisease and updates on trials for new steroid-sparing alternatives. Register here: https://hubs.li/Q025MD1y0 #SteroidToxicity #Webinar #Rheumatology #SteritasGTI #Vasculitis

The current standard treatment around the world for #IgG4RD is glucocorticoids. But is the role of steroids in treating this disease outsized? 🤔 Hear from John Stone, MD MPH and Wen Zhang, MD PhD their thoughts on the #InflammatoryDisease and updates on trials for new steroid-sparing alternatives. Register here: https://hubs.li/Q025MFg90 #SteroidToxicity #Webinar #Rheumatology #SteritasGTI #Vasculitis

It has been a real honor to contribute to the conversation around #raredisease registries through the Pulse Infoframe Inc. Patient Advisory Board. Earlier this year, a white paper was released based on those conversations. This month, the poster below was displayed at the #WORLD Orphan Drug Conference, which highlights the many opportunities for making rare disease #registries both more effective for #researchers and more inclusive of the #patient voice. Link to white paper: https://lnkd.in/gM9yNNbc #rarediseaseawareness #allsstripes #globalgenes #healthpsychology #rarepsychology #gaucherdisease #showyourgenes #nord #globalgenes #allstripes #showyourstripes #zebras

In our next #SteroidToxicity Insights Webinar, we will be joined by John Stone MD, MPH in Boston and Wen Zhang, MD PhD in Beijing to discuss treatment for IgG4-related disease (#IgG4RD). Register today for a front row seat to this engaging topic that affects patients worldwide: https://hubs.li/Q025MrVk0 #SteritasGTI #Webinar #InflammatoryDisease #Vasculitis #Rheumatology

NCP, an orphan disease that causes pain and sensitivity in the eyes, face, or head, is a large unmet medical need, and the clinical trials of OK-101 are the first to investigate a therapy for it. While the cause is unknown, NCP is thought to result from a combination of inflammation and corneal nerve damage. There are no approved therapies to relieve patients with NCP, and providers are forced to use off-label systemic and topical therapies to help patients find relief. Learn more: https://lnkd.in/eQdsfirR

Let’s make #IBDVisible during this Crohn’s and Colitis awareness week. My colleague Marta Plana Ramón shared some interesting insights on the currently approved treatment options to manage Crohn’s disease and ulcerative colitis. Today, I wanted to continue that journey and show what is in the pipeline for inflammatory bowel disease (IBD) by quickly analyzing the number of ongoing and planned interventional, commercially-sponsored clinical trials within the IBD space. An analysis brought to you by Anju Software's clinical intelligence solution TA Scan 📊 #IBD #UlcerativeColitis #CrohnsDisease #DataScience #TAScan

Implementing a clinical intelligence solution requires collaboration among pharmaceutical companies, contract research organizations (CROs), technology providers, and regulatory bodies. By harnessing the power of data and artificial intelligence, clinical trials can become more efficient, cost-effective, and successful in bringing new therapies to market. This IBD analysis is just one way that Anju Software's TA Scan solution can help make data driven decisions. #clinicaltrials #clinicaldatamanagement #pharma

Perinal fistulas remain a common subtype of Crohns Disease which cause morbidity. Several reasons why perianal fistulas don’t heal. Nicely outlined by Dr Jeff McCurdy at our Great Lakes IBD meeting These include: microbiological, drug (PK/PD), dysregulated immunity, anatomic, and aberrant tissue healing (track epithelialization and impaired tissue repair). One of the issues is that existing therapies typically only 🎯 one of these mechanisms. Glad we have dedicated clinical trials of IL23 inhibitors assessing fistula closure, but we need more programs to address this. #IBD #drugdevelopment #clinicaltrials #clinicaldevelopment

Last week, we tested your knowledge on the guidelines-based standard of care for treating #CIDP (chronic inflammatory demyelinating polyneuropathy), a chronic, progressive condition that may require long-term management. 70% of you picked the correct answer – there are several guidelines-based treatment options for CIDP: corticosteroids, immunoglobulins, and plasmapheresis. The path to diagnosis and treatment can be a long process for people living with CIDP. We’re committed to doing our part for patients and moving science forward. Learn more: https://lnkd.in/eM_9wmRe

📢 WEBINAR ALERT! Save the date for ‘The practical use of CMV inSIGHT™ (CMV T Cell Immunity testing) in the Kidney or Liver transplant recipient.’ Presented by Mary Moss Chandran, PharmD, CPP, BCTXP, BCPS, FAST, FCCP, of the University of North Carolina. UNC Health 📅 March 13th, 12-1pm CST - REGISTER NOW 👇 Topics covered include: •  Current clinical conundrums with CMV Prevention and Treatment •  Utilizing the CMV inSIGHT T cell Immunity Panel (TCIP) •  Highlighting clinical scenarios for TCIP guidance #pharmd #PYG1 #PYG2 #cmv